相关临床试验
903
512 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
40
4.4%
已完成
213
23.6%
尚未招募
472
52.3%
招募中
173
19.2%
暂无批准数据
- The Supreme Court of India ruled that stem cell therapy for Autism Spectrum Disorder outside approved clinical trials is unethical and constitutes medical malpractice due to lack of scientific evidence. - Justices declared that every use of stem cells in patients outside approved clinical trials violates medical standards and fails to meet reasonable care requirements. - The court directed the Ministry of Health to provide solutions for patients currently receiving therapy while prohibiting commercial stem cell treatments for autism. - Regulatory authorities must take action against errant clinics under existing legislation, with the court highlighting fragmented legal frameworks governing stem cell research.
- The TOPSPIN trial, led by AIIMS Delhi, found that three commonly used two-drug combination pills for hypertension showed equal effectiveness in reducing blood pressure among South Asian patients, with all combinations achieving approximately 14/8 mmHg reduction in 24-hour ambulatory measurements. - Nearly 70% of the 1,981 participants achieved blood pressure control below 140/90 mmHg after 6 months of treatment, representing a significant improvement over current national control rates in India. - All three combinations (amlodipine-perindopril, amlodipine-indapamide, and perindopril-indapamide) demonstrated similar safety profiles with less than 3% of participants discontinuing therapy due to side effects. - The study provides the first robust evidence for optimal dual combination therapy in South Asian populations, who represent a quarter of the world's population and face an enormous hypertension burden with poor control rates.
• Indigenously developed HPV test kits for cervical cancer screening were launched in Delhi, targeting the seven to eight most common cancer-causing HPV types specific to India's population. • The RTPCR-based diagnostic kits, validated through collaborative research led by AIIMS Delhi, offer a cost-effective alternative to traditional Pap smears and HPV DNA tests for national cancer screening programs. • With cervical cancer being the second most common cancer among Indian women and accounting for 25% of global mortality, these kits align with WHO's recommendation for HPV testing as the preferred screening method.
- Immuneel Therapeutics has launched Qartemi, India's first CAR T-cell therapy for treating adult B-cell Non-Hodgkin Lymphoma (B-NHL). - Qartemi is a personalized therapy that modifies a patient’s T-cells to target and eliminate cancer cells, offering hope for lasting remission. - Clinical trials in India and Spain demonstrated that Qartemi's safety and efficacy are similar to US FDA-approved CAR T-cell therapies. - Priced at approximately ₹35 to ₹50 lakh, Qartemi is significantly more affordable than similar treatments in the US.
